https://www.scmp.com/rss/517814/feed CSPC Pharmaceutical researches, develops, manufactures and sells pharmaceutical products. It produces active pharmaceutical ingredients as well as formulations. The company's manufacturing facilities are primarily located in Hebei province. en https://assets.i-scmp.com/static/img/icons/scmp-meta-1200x630.png https://www.scmp.com Julie Zhang Julie Zhang The State Council, China’s cabinet, has published guidelines on innovative drug pricing that a bank analyst has described as the “most significant” in a decade, as they aim to reward drug innovation and ease pricing tension for domestic and multinational pharmaceutical companies. The framework document published this month said patented innovative drugs would be supported through value-based pricing, while the prices of generic drugs would be driven down through market competition and... https://www.scmp.com/business/banking-finance/article/3350956/multinational-pharmaceutical-companies-benefit-new-china-guidelines-analysts?utm_source=rss_feed https://www.scmp.com/business/banking-finance/article/3350956/multinational-pharmaceutical-companies-benefit-new-china-guidelines-analysts?utm_source=rss_feed Wed, 22 Apr 2026 05:00:09 +0000 Daniel Ren Daniel Ren The cross-border outlicensing activities of Chinese biotech firms reached a record transaction value of US$60 billion in the first quarter of 2026, driven by multinational pharmaceutical companies’ growing appetite for the country’s promising drug candidates. The deal value represented a 73 per cent jump from the same period a year earlier, and accounted for nearly half of the total US$135.7 billion worth of agreements signed throughout 2025, the National Medical Products Administration (NMPA)... https://www.scmp.com/business/china-business/article/3348295/china-biotech-deals-hit-record-innovative-drugs-draw-interest-multinationals?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3348295/china-biotech-deals-hit-record-innovative-drugs-draw-interest-multinationals?utm_source=rss_feed Sun, 29 Mar 2026 11:26:21 +0000 Cao Li Cao Li Hong Kong stocks fell on Wednesday as tech firms slid after Chinese authorities moved to curb the OpenClaw frenzy. The Hang Seng Index edged down 0.2 per cent to close at 25,898.76 after gaining as much as 0.7 per cent in the morning session. The Hang Seng Tech Index fell 0.1 per cent. On the mainland, the CSI 300 Index added 0.6 per cent and the Shanghai Composite Index gained 0.3 per cent. On Tuesday, China’s cybersecurity emergency response system warned of security and data risks tied to... https://www.scmp.com/business/markets/article/3346160/hong-kong-stocks-extend-rebound-proposed-release-oil-reserve-soothes-fears?utm_source=rss_feed https://www.scmp.com/business/markets/article/3346160/hong-kong-stocks-extend-rebound-proposed-release-oil-reserve-soothes-fears?utm_source=rss_feed Wed, 11 Mar 2026 02:10:04 +0000 Julie Zhang Julie Zhang The pace and size of outlicensing deals between Chinese drug makers and global partners have accelerated this year, highlighted by two agreements announced this week, each worth more than US$1 billion. The string of deals shows how China is becoming a sought-after source of drug candidates for multinational pharmaceutical companies, which are increasingly looking for long-term partnerships rather than one-off arrangements, analysts said. The latest deals, Sino Biopharmaceutical’s agreement with... https://www.scmp.com/business/china-business/article/3345404/china-outlicensing-tops-us52-billion-first-two-months-rise-global-deals?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3345404/china-outlicensing-tops-us52-billion-first-two-months-rise-global-deals?utm_source=rss_feed Wed, 04 Mar 2026 09:30:11 +0000 Zhang Shidong,Yulu Ao Zhang Shidong,Yulu Ao Hong Kong stocks gained, extending a rebound from a sell-off in technology companies, as traders returned to the risk-on mode on bets that the tumult has run its course. The Hang Seng Index rose 0.6 per cent to 27,183.15 at the close. The Hang Seng Tech Index climbed 0.6 per cent. On the mainland, the CSI 300 Index and the Shanghai Composite Index both added 0.1 per cent. Pharmaceutical firm CSPC Pharmaceutical Group rallied 5.5 per cent to HK$10.32, and biotech firm Innovent Biologics gained 5... https://www.scmp.com/business/china-business/article/3342992/hong-kong-stocks-extend-bounce-back-tech-turbulence-risk-sentiment-returns?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3342992/hong-kong-stocks-extend-bounce-back-tech-turbulence-risk-sentiment-returns?utm_source=rss_feed Tue, 10 Feb 2026 02:58:48 +0000 Julie Zhang Julie Zhang Foreign and mainland Chinese drug makers are fighting for a multibillion-dollar slice of the domestic weight-loss market by slashing prices by as much as 80 per cent, as China faces a worsening obesity crisis. Competition in the sector, dominated by global pharmaceutical giants Novo Nordisk and Eli Lilly, intensified after both secured obesity-drug approvals in China in 2024. The landscape is set to shift further when the patent on Novo Nordisk’s semaglutide expires in March in China, opening... https://www.scmp.com/business/china-business/article/3339544/chinas-weight-loss-drug-war-prices-slashed-80-obesity-crisis-worsens?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3339544/chinas-weight-loss-drug-war-prices-slashed-80-obesity-crisis-worsens?utm_source=rss_feed Mon, 12 Jan 2026 23:30:09 +0000 Cao Li Cao Li Hong Kong stocks rallied on Monday, lifted by gains in healthcare and technology shares, while daily turnover on mainland China’s exchanges surged to a record high. The Hang Seng Index climbed 1.4 per cent to close at 26,608.48, while the Hang Seng Tech Index climbed 2.9 per cent. On the mainland, the CSI 300 Index advanced 0.65 per cent and the Shanghai Composite Index gained 1.1 per cent. Trading volume on the Shanghai and Shenzhen exchanges shares hit a record 3.58 trillion yuan (US$513.2... https://www.scmp.com/business/article/3339531/hong-kong-stocks-edge-higher-tech-and-pharmaceutical-gains?utm_source=rss_feed https://www.scmp.com/business/article/3339531/hong-kong-stocks-edge-higher-tech-and-pharmaceutical-gains?utm_source=rss_feed Mon, 12 Jan 2026 02:33:43 +0000 Zhang Shidong Zhang Shidong Hong Kong stocks rose for a third day on Friday, sending the benchmark gauge to its longest winning streak in three weeks, after softer US inflation data bolstered the case for monetary easing and allayed concerns about frothy valuations of global equities. The Hang Seng Index advanced 0.8 per cent to 25,690.53 at the close, paring the weekly loss to 1.1 per cent. The Hang Seng Tech Index gained 1.1 per cent. On the mainland, the CSI 300 Index climbed 0.3 per cent and the Shanghai Composite... https://www.scmp.com/business/china-business/article/3336987/hong-kong-stocks-head-longest-rising-streak-3-weeks-cooling-us-inflation-data?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3336987/hong-kong-stocks-head-longest-rising-streak-3-weeks-cooling-us-inflation-data?utm_source=rss_feed Fri, 19 Dec 2025 02:28:46 +0000 Cao Li Cao Li Hong Kong stocks extended a rally on Tuesday as investors continued to bet on easing US-China trade tensions. The Hang Seng Index rose 0.7 per cent to 26,027.55 at the close after climbing as much as 2 per cent earlier. The Hang Seng Tech Index surged 1.3 per cent. On the mainland, the CSI 300 Index gained 1.5 per cent and the Shanghai Composite Index added 1.4 per cent. China Life jumped 6 per cent to HK$24.95, BYD Electronic rose 3.8 per cent to HK$40.22 and machine-tool maker Techtronic... https://www.scmp.com/business/markets/article/3329733/hong-kong-stock-rally-carries-investors-bet-us-china-trade-agreement?utm_source=rss_feed https://www.scmp.com/business/markets/article/3329733/hong-kong-stock-rally-carries-investors-bet-us-china-trade-agreement?utm_source=rss_feed Tue, 21 Oct 2025 02:22:27 +0000 Eric Ng,Julie Zhang Eric Ng,Julie Zhang When Zhao Hong, chief doctor of China’s leading cancer hospital at the Chinese Academy of Medical Sciences, told his fellow delegates at a Communist Party meeting in March that a little-known Guangzhou biotech firm’s cancer drug had beaten the world’s bestselling medicine, investors took notice. “As a long-serving front-line doctor, my most profound feeling is that China is at the best time of its biopharmaceutical sector’s development,” he told state media on the sidelines of the annual Chinese... https://www.scmp.com/business/china-business/article/3327701/chinas-biotech-renaissance-rising-drug-creation-prowess-attracts-global-notice?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3327701/chinas-biotech-renaissance-rising-drug-creation-prowess-attracts-global-notice?utm_source=rss_feed Sat, 04 Oct 2025 02:00:09 +0000 Zhang Shidong Zhang Shidong A rally that sent Hong Kong stocks to the highest level in four years took a breather, as Chinese drug makers took a pounding amid fears that the Trump administration would impose fresh curbs on medicine exports from the country. The Hang Seng Index closed 0.4 per cent lower at 26,086.32 on Thursday, trimming a decline of as much as 1.2 per cent. The Hang Seng Tech Index slipped 0.2 per cent. A rebound in mainland stocks helped to ease the selling pressure in the city. The CSI 300 Index climbed... https://www.scmp.com/business/china-business/article/3325115/hong-kong-stocks-slip-4-year-high-amid-fears-us-sanctions-chinese-drug-makers?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3325115/hong-kong-stocks-slip-4-year-high-amid-fears-us-sanctions-chinese-drug-makers?utm_source=rss_feed Thu, 11 Sep 2025 02:33:19 +0000 Eric Ng Eric Ng A potential multibillion-dollar deal unveiled on Friday by CSPC Pharmaceutical Group is the latest in a growing number of agreements by Chinese biotechnology firms to license development rights for innovative medicines to global pharmaceutical firms, according to lawyers advising the companies. Many of these deals use a so-called newco structure, which combines traditional intellectual property licensing with fundraising via a newly established corporate vehicle, said the Shanghai-based partners... https://www.scmp.com/business/article/3312416/chinese-biotechs-mega-drug-licensing-deals-multinationals-surge-cost-savings?utm_source=rss_feed https://www.scmp.com/business/article/3312416/chinese-biotechs-mega-drug-licensing-deals-multinationals-surge-cost-savings?utm_source=rss_feed Fri, 30 May 2025 05:30:38 +0000 Zhang Shidong Zhang Shidong Hong Kong stocks capped a sixth straight weekly gain on optimism that a de-escalation in US-China tensions will dispel the gloom surrounding China’s growth outlook, alongside last month’s data pointing to a mild ongoing recovery. The Hang Seng Index closed 0.2 per cent higher at 23,601.26. The benchmark added 1.1 per cent this week, the longest winning stretch in three months. The Hang Seng Tech Index slipped 0.1 per cent. On the mainland, the CSI 300 Index dropped 0.8 per cent and the Shanghai... https://www.scmp.com/business/china-business/article/3311469/hong-kong-stocks-track-sixth-week-gains-upbeat-china-outlook?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3311469/hong-kong-stocks-track-sixth-week-gains-upbeat-china-outlook?utm_source=rss_feed Fri, 23 May 2025 02:42:08 +0000 Zhang Shidong Zhang Shidong Hong Kong stocks rose on Tuesday, with the benchmark climbing to a two-month high after China cut key interest rates for the first time in seven months. The Hang Seng Index closed 1.5 per cent higher at 23,681.48, a level not seen since March 24. The Hang Seng Tech Index added 1.2 per cent. On the mainland, the CSI 300 Index climbed 0.5 per cent and the Shanghai Composite Index advanced 0.4 per cent. Morgan Stanley’s upbeat view on China’s pharmaceutical industry boosted drug makers, which led... https://www.scmp.com/business/china-business/article/3310996/hong-kong-stocks-rise-after-china-cuts-borrowing-costs-first-time-7-months?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3310996/hong-kong-stocks-rise-after-china-cuts-borrowing-costs-first-time-7-months?utm_source=rss_feed Tue, 20 May 2025 02:17:47 +0000 Aileen Chuang Aileen Chuang Hong Kong stocks rose slightly on Tuesday, as traders kept an eye on the latest developments in the US-China tariff talks and corporate results to assess the impact of the ongoing trade war. The Hang Seng Index closed 0.2 per cent higher at 22,008.11. The Hang Seng Tech Index gained 0.6 per cent. On the mainland, the CSI 300 Index dropped 0.2 per cent and the Shanghai Composite Index fell 0.1 per cent. Chinese biotech firm WuXi AppTec rose 4.2 per cent to HK$60.65 after net income beat analysts’... https://www.scmp.com/business/markets/article/3308288/hong-kong-stocks-rise-investors-await-earnings-hsbc-icbc-china-construction-bank?utm_source=rss_feed https://www.scmp.com/business/markets/article/3308288/hong-kong-stocks-rise-investors-await-earnings-hsbc-icbc-china-construction-bank?utm_source=rss_feed Tue, 29 Apr 2025 02:40:01 +0000 Eric Ng Eric Ng Licensing deals struck by Chinese biotech start-ups with overseas partners could potentially fetch billions in revenue if their drug candidates are successfully developed and launched, according to analysts. “One of the few highlights in the lacklustre sector was the strong deal flow from Chinese sellers to overseas buyers – mostly from the US – of preclinical or clinical-stage molecules, on so-called asset out-licensing or business development,” Zhang Jialin, head of China healthcare research,... https://www.scmp.com/business/china-business/article/3296809/chinese-biotech-firms-cash-promising-drug-discoveries-licensing-deals?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3296809/chinese-biotech-firms-cash-promising-drug-discoveries-licensing-deals?utm_source=rss_feed Fri, 31 Jan 2025 09:00:08 +0000 Eric Ng Eric Ng China has added dozens of new drugs to its health insurance reimbursement list, signalling support for innovative treatments while keeping a tight control on spending. The National Healthcare Security Administration on Thursday pre-approved 91 medicines, taking the total to 3,159. Meanwhile, 43 drugs that have with better alternatives or that are no longer manufactured were ejected. The additions comprise 26 anti-tumour drugs, 15 for treating diabetes and other chronic diseases, 13 rare disease... https://www.scmp.com/business/article/3288691/china-expands-health-insurance-coverage-91-new-drugs-breakthrough-treatments?utm_source=rss_feed https://www.scmp.com/business/article/3288691/china-expands-health-insurance-coverage-91-new-drugs-breakthrough-treatments?utm_source=rss_feed Fri, 29 Nov 2024 08:42:27 +0000 China’s health authorities have approved clinical trials of two Covid-19 vaccines that use mRNA, potentially adding an option to the nation’s arsenal in its battle against the pandemic’s worst outbreak since 2020. CanSino Biologics and CSPC Pharmaceutical have been approved by the National Medical Products Administration of China (NMPA) to commence trials, according to statements by the two companies. CanSino’s stock price in Hong Kong closed 5.9 per cent higher at HK$132.90 on Monday morning.... https://www.scmp.com/business/china-business/article/3172972/china-approves-cspc-cansino-mrna-vaccines-clinical-trial?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3172972/china-approves-cspc-cansino-mrna-vaccines-clinical-trial?utm_source=rss_feed Mon, 04 Apr 2022 04:06:18 +0000 CSPC Pharmaceutical Group saw its share price fall 6.7 per cent to HK$6.28 yesterday after the company announced the discounted sale of an 11.95 per cent stake in the firm to a third party to cash out HK$4.4 billion. More than 661 million shares changed hands in the heaviest single day of trading in the company's history. John Zhao Huan, an executive director of CSPC, sold 600 million shares yesterday to third parties and 105.88 million shares to CSPC chairman Cai Dongchen at HK$6.25 per... https://www.scmp.com/business/money/markets-investing/article/1520185/cspc-shares-plunge-after-director-john-zhao-huan?utm_source=rss_feed https://www.scmp.com/business/money/markets-investing/article/1520185/cspc-shares-plunge-after-director-john-zhao-huan?utm_source=rss_feed Tue, 27 May 2014 17:00:41 +0000